Development and maintenance of consensus recommendations on pediatric outpatient antibiotic therapy in Germany: a framework for rational use
European Journal of Pediatrics · 2025
DOI: 10.1007/s00431-024-05964-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pediatrics, 2025. Verfasst von Janina Soler Wenglein und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Protestant Hospital of the Bethel Foundation, Medical School and University Medical Center OWL, Bielefeld University, Biele…. Hauptthemen laut MEDLINE: Ambulatory Care, Anti-Bacterial Agents, Antimicrobial Stewardship, Pediatrics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Bielefeld.
Abstract (Originalsprache)
In pediatric outpatient care, overuse and misuse of antibiotics is linked to a high risk of adverse events and increased antibiotic resistance. In 2019, building upon the work of the Antibiotic Therapy in Bielefeld (AnTiB) project (founded in 2016), a collaboration among the AnTiB, the German Society for Pediatric Infectious Diseases (DGPI), and the Professional Association of Outpatient Pediatricians and Adolescent Physicians (BVKJ) was established to develop consensus recommendations for antibiotic therapy in pediatric outpatient settings in Germany. This working group became the Antibiotic Stewardship in Outpatient Pediatrics (ABSaP). ABSaP institutes recommendations for antibiotic use in outpatient pediatric settings in Germany and updates them regularly. The ABSaP guidelines recommend restrictive, targeted, evidence-based prescription practices for antibiotics used to treat common infections among pediatric outpatients. This expert-driven, pragmatic, best-practice guidance is designed to be a living document. ABSaP’s most recent update was published in March 2024. The recommendations aim to guide and standardize rational antibiotics use by emphasizing the importance of avoiding unnecessary prescriptions, while also promoting the application of narrow-spectrum antibiotics, short-duration therapy, and watchful waiting, when treating mild, self-limiting infections in children without significant risk factors. Conclusions : ABSaP’s guidelines may provide a model for others, as well as offer a basis for discussing practical, effective antibiotic stewardship (ABS) measures in pediatric primary care. An international, expert consensus on ABS for pediatric outpatients could help promote a culture of responsible antibiotic use, improve prescribing safety, and contribute to broader ABS efforts. What is Known: • Overuse and misuse of antibiotics are associated with adverse events and increased antibiotic resistance, prompting the need for effective antibiotic stewardship initiatives. • The Antibiotic Stewardship in Outpatient Pediatrics (ABSaP) working group was established to develop and regularly update evidence-based best practice recommendations for the targeted and restrictive use of antibiotics in pediatric outpatient settings in Germany. What is New: • The most recent update of the ABSaP guidelines was published in March 2024, emphasizing the importance of narrow-spectrum antibiotics, short-duration therapy, and watchful waiting for mild infections, aiming to standardize rational antibiotic use in children. • The ABSaP guidelines have become widely accepted in Germany and are now being translated into English to foster international dialogue and collaboration on antibiotic stewardship in pediatric primary care, potentially serving as a model for similar initiatives in other countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Protestant Hospital of the Bethel Foundation, Medical School and University Medical Center OWL, Bielefeld University, Bielefeld, Germany. janina.soler@uni-bielefeld.de.
- Laboratory of Experimental Pediatric Pneumology and Allergology, Center for Biomedical Education and Science (ZBAF), Department of Human Medicine, Faculty of Medicine, Witten/Herdecke University, Witten, Germany. janina…
- Medical School OWL, Bielefeld University, Bielefeld, Germany. janina.soler@uni-bielefeld.de.
- Pediatric Oncology and Hematology, Pediatric Infectious Diseases, Children's Hospital, Saarland University Medical Center, Homburg, Germany.
- Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Praxis für Kinder und Jugendliche Holger Brockmeyer, Hamburg, Germany.
Förderung
- Universität Bielefeld
Zitieren
APA
Soler Wenglein, J., Simon, A., Berner, R., Brockmeyer, H., Forster, J., Hamelmann, E., Klein, W., Liese, J., Neubert, J., Pfeil, J., Renk, H., Tenenbaum, T., Toepfner, N., further ABSaP Working Group members, Hufnagel, M., & Tillmann, R. (2025). Development and maintenance of consensus recommendations on pediatric outpatient antibiotic therapy in Germany: a framework for rational use. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05964-y
Vancouver
Soler Wenglein J, Simon A, Berner R, Brockmeyer H, Forster J, Hamelmann E, et al. Development and maintenance of consensus recommendations on pediatric outpatient antibiotic therapy in Germany: a framework for rational use. European Journal of Pediatrics. 2025. doi:10.1007/s00431-024-05964-y
BibTeX
@article{SolerWenglein2025,
author = {Soler Wenglein, Janina and Simon, Arne and Berner, Reinhard and Brockmeyer, Holger and Forster, Johannes and Hamelmann, Eckard and Klein, Wolfgang and Liese, Johannes and Neubert, Jennifer and Pfeil, Johannes and Renk, Hanna and Tenenbaum, Tobias and Toepfner, Nicole and further ABSaP Working Group members, further ABSaP Working Group members and Hufnagel, Markus and Tillmann, Roland},
title = {Development and maintenance of consensus recommendations on pediatric outpatient antibiotic therapy in Germany: a framework for rational use},
journal = {European Journal of Pediatrics},
year = {2025},
doi = {10.1007/s00431-024-05964-y}
}
EUVIMED